{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-035603","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.591107+00:00","generated_at":"2026-05-31T11:51:23.710887+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lyell Immunopharma Q2 net loss narrows to $45.8M; LYL797 shows 40% ORR in TNBC","bullets":["Net loss of $45.8M ($63.9M in Q2 2023); non-GAAP net loss $39.1M ($45.6M).","Cash, equivalents and marketable securities $491.1M as of June 30, 2024, funding operations into 2027.","LYL797 Phase 1: 40% objective response rate and 60% clinical benefit rate at 150x10^6 cells in relapsed/refractory TNBC.","FDA cleared IND for LYL119 (next-gen ROR1 CAR T); Phase 1 to start in ROR1+ ovarian/endometrial cancers.","R&D expenses decreased to $40.3M; G&A expenses to $12.3M, driven by November 2023 workforce reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-035603","json":"https://secwatch.observer/filing/0001628280-24-035603.json","markdown":"https://secwatch.observer/filing/0001628280-24-035603.md","text":"https://secwatch.observer/filing/0001628280-24-035603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828024035603/0001628280-24-035603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828024035603/lyel-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:51:23.710887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}